Canada In Vitro Diagnostics Market Outlook to 2017 – Clinical Chemistry Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What is This Report About?
3 In Vitro Diagnostics In Canada
3.1 In Vitro Diagnostics, Market Segmentation
3.2 In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, 2003-2017
3.3 In Vitro Diagnostics Market, Canada, Revenue Mix ($m), 2010
3.4 In Vitro Diagnostics Market, Canada, Category Contribution (%), 2010
3.5 In Vitro Diagnostics, Canada, Company share (2009-2010)
4 Clinical Chemistry In Canada
4.1 Clinical Chemistry, Market Segmentation
4.2 Clinical Chemistry Market, Canada, Revenue Mix ($m), 2010
4.3 Clinical Chemistry Market, Canada, Segment Contribution (%), 2010
4.4 Clinical Chemistry Overall Revenue (2003-2017)
4.4.1 Clinical Chemisty Analyzers Revenue (2003-2017)
4.4.2 Urine Analysis Revenue (2003-2017)
4.5 Clinical Chemistry Distribution Share (2009-2010)
4.6 Clinical Chemistry, Canada, Company share (2009-2010)
5 Genetic Testing In Canada
5.1 Genetic Testing, Market Segmentation
5.2 Genetic Testing Market, Canada, Revenue Mix ($m), 2010
5.3 Genetic Testing Market, Canada, Segment Contribution (%), 2010
5.4 Genetic Testing Overall Revenue (2003-2017)
5.5 Genetic Testing Distribution Share (2009-2010)
5.6 Genetic Testing, Canada, Company share (2009-2010)
6 Haematology In Canada
6.1 Haematology, Market Segmentation
6.2 Haematology Market, Canada, Revenue Mix ($m), 2010
6.3 Haematology Market, Canada, Segment Contribution (%), 2010
6.4 Haematology Overall Revenue (2003-2017)
6.4.1 Haematology Reagents Revenue (2003-2017)
6.4.2 Immunohaematology Revenue (2003-2017)
6.4.3 Haemostasis Revenue (2003-2017)
6.4.4 Haematology Rapid Tests Revenue (2003-2017)
6.4.5 Haematology Cell Counters Revenue (2003-2017)
6.5 Haematology Distribution Share (2009-2010)
6.6 Haematology, Canada, Company share (2009-2010)
7 Histology And Cytology In Canada
7.1 Histology And Cytology, Market Segmentation
7.2 Histology And Cytology Market, Canada, Revenue Mix ($m), 2010
7.3 Histology And Cytology Market, Canada, Segment Contribution (%), 2010
7.4 Histology And Cytology Overall Revenue (2003-2017)
7.5 Histology And Cytology Distribution Share (2009-2010)
7.6 Histology And Cytology, Canada, Company share (2009-2010)
8 Immuno Chemistry In Canada
8.1 Immuno Chemistry Market, Canada, Revenue Mix ($m), 2010
8.2 Immuno Chemistry Market, Canada, Segment Contribution (%), 2010
8.3 Immuno Chemistry Overall Revenue (2003-2017)
8.3.1 Disease Specific Immunochemistry Revenue (2003-2017)
8.3.2 Drugs of Abuse / Toxicology Revenue (2003-2017)
8.3.3 Endocrinology Tests Revenue (2003-2017)
8.3.4 Therapeutic Drug Monitoring Revenue (2003-2017)
8.3.5 Immunochemistry Analyzers Revenue (2003-2017)
8.4 Immuno Chemistry Distribution Share (2009-2010)
8.5 Immuno Chemistry, Canada, Company share (2009-2010)
9 Infectious Immunology In Canada
9.1 Infectious Immunology, Market Segmentation
9.2 Infectious Immunology Market, Canada, Revenue Mix ($m), 2010
9.3 Infectious Immunology Market, Canada, Segment Contribution (%), 2010
9.4 Infectious Immunology Overall Revenue (2003-2017)
9.5 Infectious Immunology Distribution Share (2009-2010)
9.6 Infectious Immunology, Canada, Company share (2009-2010)
10 Microbiology Culture In Canada
10.1 Microbiology Culture, Market Segmentation
10.2 Microbiology Culture Market, Canada, Revenue Mix ($m), 2010
10.3 Microbiology Culture Market, Canada, Segment Contribution (%), 2010
10.4 Microbiology Culture Overall Revenue (2003-2017)
10.4.1 Microbiology Analyzers Revenue (2003-2017)
10.5 Microbiology Culture Distribution Share (2009-2010)
10.6 Microbiology Culture, Canada, Company share (2009-2010)
11 Overview of Key Companies in Canada In Vitro Diagnostics Market
11.1 Siemens Healthcare
11.1.1 Company Overview
11.1.2 Share in the Canada In Vitro Diagnostics Market
11.2 Abbott Laboratories
11.2.1 Company Overview
11.2.2 Share in the Canada In Vitro Diagnostics Market
11.3 F. Hoffmann-La Roche Ltd.
11.3.1 Company Overview
11.3.2 Share in the Canada In Vitro Diagnostics Market
11.4 Beckman Coulter, Inc.
11.4.1 Company Overview
11.4.2 Share in the Canada In Vitro Diagnostics Market
11.5 Ortho-Clinical Diagnostics Inc.
11.5.1 Company Overview
11.5.2 Share in the Canada In Vitro Diagnostics Market
11.6 bioMerieux S.A.
11.6.1 Company Overview
11.6.2 Share in the Canada In Vitro Diagnostics Market
11.7 Becton, Dickinson and Company
11.7.1 Company Overview
11.8 Bio-Rad Laboratories, Inc.
11.8.1 Company Overview
11.9 Biomedica Diagnostics Inc.
11.9.1 Company Overview
11.10 Sysmex Corporation
11.10.1 Company Overview
11.11 Qiagen N.V.
11.11.1 Company Overview
11.12 Immucor, Inc.
11.12.1 Company Overview
11.13 Alere Inc.
11.13.1 Company Overview
11.14 Gen-Probe Incorporated
11.14.1 Company Overview
11.15 DiaSorin S.p.A
11.15.1 Company Overview
11.16 Thermo Fisher Scientific Inc.
11.16.1 Company Overview
11.17 Phadia AB
11.17.1 Company Overview
11.18 Hologic, Inc.
11.18.1 Company Overview
11.19 Grifols, S.A.
11.19.1 Company Overview
11.20 Life Technologies Corporation
11.20.1 Company Overview
11.21 HORIBA, Ltd.
11.21.1 Company Overview
11.22 PerkinElmer, Inc.
11.22.1 Company Overview
12 In Vitro Diagnostics Market Pipeline Products
12.1 Clinical Chemisty Market Pipeline Products
12.2 Immuno Chemistry Market Pipeline Products
12.3 Haematology Market Pipeline Products
12.4 Infectious Immunology Market Pipeline Products
12.5 Microbiology Culture Market Pipeline Products
12.6 Histology And Cytology Market Pipeline Products
12.7 Genetic Testing Market Pipeline Products
13 Financial Deals Landscape
13.1 Merger
13.1.1 Transonic Systems Merges with Scisense
13.2 Acquisition
13.2.1 Modern Mobility Aids Finalizes Acquisition Of LumiGene Technologies
13.2.2 OraSure Technologies Completes Acquisition Of DNA Genotek
13.2.3 Trinity Biotech Acquires Phoenix Bio-Tech
13.3 Partnerships
13.3.1 Sony DADC Enters Into Co-Development Agreement With Axela
13.3.2 Genome British Columbia Enters Into Co-Development Agreement With Genome Canada
13.3.3 WILEX Enters Into Co-Marketing Agreement With ALPCO Diagnostics
13.3.4 Warnex Medical Laboratories Enters Into Distribution Agreement With deCODE genetics
13.3.5 Warnex PRO-DNA Enters Into Co-Development Agreement With National Research Council of Canada
13.3.6 Warnex Enters Into Licensing Agreement With Sorenson Forensics
13.3.7 Roche Enters Into Distribution Agreement With PerkinElmer
13.3.8 Pronexus Enters Into Technology Integration Agreement With RealityCorp
13.3.9 Carl Zeiss Enters Into Licensing Agreement With Prior Scientific
13.3.10 Stratos Product Development Enters Into Co-Development Agreement With Response Biomedical
13.3.11 Signal Genetics Enters Into Research And Development Agreement With DiagnoCure
13.3.12 Pivotal Therapeutics Enters Into Co-Marketing Agreement With Nutrasource Diagnostics
13.3.13 Mitomics Enters Into Licensing Agreement With QDx Pathology Services
13.3.14 Biofortuna Enters Into Distribution Agreement With Abbott
13.3.15 CML HealthCare Enters Into Licensing Agreement With Phenomenome Discoveries
13.3.16 Magellan BioScience Enters Into An Agreement With miacom diagnostics
13.3.17 Affymetrix Enters Into Distribution Agreement With Thermo Fisher
14 Recent Developments
14.1 Strategy and Business Planning
14.1.1 Dec 20, 2011: Warnex To Sell Analytical Services Division
14.1.2 Nov 30, 2011: SQI Diagnostics Announces Realignment Of Business And Reductions In Operating Expenses To Better Serve Its IVD And CustomPlex Businesses
14.1.3 Oct 04, 2011: Roche To Expand Coagulation Testing Portfolio, Develop New Systems For Diagnostic Laboratories In US And Canada By 2014
14.1.4 May 26, 2011: New England Biolabs Opens New Subsidiary Office In France
14.1.5 Mar 14, 2011: Pacgen Announces Corporate Transformation
14.2 Legal and Regulatory
14.2.1 Feb 24, 2011: Med Biogene Charged With Fraud and Precision Therapeutics Charged With Tortious Interference In Amended Complaint by Signal Genetics
14.3 Government and Public Interest
14.3.1 Dec 21, 2011: Miraculins Successfully Passes Critical ISO 13485 Certification Audit
14.3.2 Oct 05, 2011: Norgen Biotek Achieves Accreditation To ISO 15189:2007 For Molecular Diagnostic Testing And Clinical Trials
14.3.3 Sep 21, 2011: Aeterna Zentaris To Present At Sixth Annual JMP Securities Healthcare Conference
14.3.4 Aug 02, 2011: Noninvasive Fecal Occult Blood Test Effective Screen For Lower GI Tract Lesions: Study
14.3.5 Jul 28, 2011: Verisante Obtains ISO Certification Of Quality Management System For Medical Device Manufacturing
14.3.6 Jul 04, 2011: UBC's Megapixel DNA Replication Technology Promises Faster, More Precise Diagnostics
14.3.7 Jun 16, 2011: Researchers At Queen's University Develop First Diagnostic Test For Hereditary Children's Disease
14.4 Product News
14.4.1 Dec 19, 2011: British Columbia Cancer Agency Joins Illumina Genome Network
14.4.2 Oct 12, 2011: Affymetrix Releases Axiom Genome-Wide Pan-African Array
14.4.3 Oct 12, 2011: GeneDx Unveils XomeDx Test To Identify Rare Inherited Diseases
14.4.4 Oct 12, 2011: NanoString Launches Second Generation nCounter Analysis System
14.4.5 Oct 11, 2011: RainDance Technologies Launches ThunderStorm System At 12th ICHG In Montreal, Canada
14.4.6 Aug 31, 2011: CaridianBCT Launches Mononuclear Cell Collection Protocol For Spectra Optia Apheresis System In Canada
14.4.7 Aug 30, 2011: Aeterna Zentaris Announces Favorable Top-Line Results Of Completed Phase III Study On AEZS-130 As First Oral Diagnostic Test For Adult Growth Hormone Deficiency
14.4.8 Aug 22, 2011: Gen-Probe Receives Canadian Regulatory Clearance For PANTHER System
14.4.9 Aug 18, 2011: RPS Receives Health Canada Approval For RPS InflammaDry Detector
14.4.10 Jul 15, 2011: Sentinel Principle Used To Discover Blood Based Biomarkers To Predict Risk Of Liver Cancer From Patients With Chronic Hepatitis: GeneNews
14.4.11 Jul 06, 2011: Axial Biotech Signs Agreement With Shriners Hospital for Children To Provide SCOLISCORE AIS Prognostic Test
14.4.12 May 06, 2011: DiagnoCure To Present Previstage GCC Test At ASCRS In Canada
14.4.13 Feb 22, 2011: CardioGenics Receives Canadian Patent For QL Care Analyzer Core Technology
14.4.14 Feb 08, 2011: PinPointe Receives FDA Approval For PinPointe FootLaser In Canada
15 Appendix
15.1 Definitions of Markets Covered in the Report
15.1.1 In Vitro Diagnostics
15.2 Research Methodology
15.3 Secondary Research
15.4 Primary Research
15.5 Models
15.6 Forecasts
15.7 Expert Panels
15.8 GlobalData Consulting
15.9 Currency Conversion
15.10 Contact Us
15.11 Disclaimer
List Of Tables
Table 1: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, 2003-2017
Table 2: In Vitro Diagnostics Market, Canada, Category Contribution (%), 2010
Table 3: In Vitro Diagnostics, Canada, Cross-Category Analysis, 2003-2017
Table 4: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, Historic, 2003-2010
Table 5: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
Table 6: In Vitro Diagnostics, Canada, Company share by Revenue ($m), USD Actual, 2009-2010
Table 7: Clinical Chemistry Market, Canada, Segment Contribution (%), 2010
Table 8: Clinical Chemistry, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 9: Clinical Chemistry, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 10: Clinical Chemisty Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 11: Clinical Chemisty Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 12: Urine Analysis, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 13: Urine Analysis, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 14: Clinical Chemistry, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 15: Clinical Chemistry, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 16: Genetic Testing Market, Canada, Segment Contribution (%), 2010
Table 17: Genetic Testing, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 18: Genetic Testing, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 19: Genetic Testing, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 20: Genetic Testing, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 21: Haematology Market, Canada, Segment Contribution (%), 2010
Table 22: Haematology, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 23: Haematology, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 24: Haematology Reagents, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 25: Haematology Reagents, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 26: Immunohaematology, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 27: Immunohaematology, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 28: Haemostasis, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 29: Haemostasis, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 30: Haematology Rapid Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 31: Haematology Rapid Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 32: Haematology Cell Counters, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 33: Haematology Cell Counters, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 34: Haematology, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 35: Haematology, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 36: Histology And Cytology Market, Canada, Segment Contribution (%), 2010
Table 37: Histology And Cytology, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 38: Histology And Cytology, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 39: Histology And Cytology, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 40: Histology And Cytology, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 41: Immuno Chemistry Market, Canada, Segment Contribution (%), 2010
Table 42: Immuno Chemistry, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 43: Immuno Chemistry, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 44: Disease Specific Immunochemistry, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 45: Disease Specific Immunochemistry, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 46: Drugs of Abuse / Toxicology, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 47: Drugs of Abuse / Toxicology, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 48: Endocrinology Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 49: Endocrinology Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 50: Therapeutic Drug Monitoring, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 51: Therapeutic Drug Monitoring, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 52: Immunochemistry Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 53: Immunochemistry Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 54: Immuno Chemistry, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 55: Immuno Chemistry, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 56: Infectious Immunology Market, Canada, Segment Contribution (%), 2010
Table 57: Infectious Immunology, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 58: Infectious Immunology, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 59: Infectious Immunology, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 60: Infectious Immunology, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 61: Microbiology Culture Market, Canada, Segment Contribution (%), 2010
Table 62: Microbiology Culture, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 63: Microbiology Culture, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 64: Microbiology Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 65: Microbiology Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 66: Microbiology Culture, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 67: Microbiology Culture, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 68: Clinical Chemisty Market Pipeline Products
Table 69: Immuno Chemistry Market Pipeline Products
Table 70: Haematology Market Pipeline Products
Table 71: Infectious Immunology Market Pipeline Products
Table 72: Microbiology Culture Market Pipeline Products
Table 73: Histology And Cytology Market Pipeline Products
Table 74: Genetic Testing Market Pipeline Products
Table 75: Transonic Systems Merges With Scisense
Table 76: Modern Mobility Aids Finalizes Acquisition Of LumiGene Technologies
Table 77: OraSure Technologies Completes Acquisition Of DNA Genotek
Table 78: Trinity Biotech Acquires Phoenix Bio-Tech
Table 79: Sony DADC Enters Into Co-Development Agreement With Axela
Table 80: Genome British Columbia Enters Into Co-Development Agreement With Genome Canada
Table 81: WILEX Enters Into Co-Marketing Agreement With ALPCO Diagnostics
Table 82: Warnex Medical Laboratories Enters Into Distribution Agreement With deCODE genetics
Table 83: Warnex PRO-DNA Enters Into Co-Development Agreement With National Research Council of Canada
Table 84: Warnex Enters Into Licensing Agreement With Sorenson Forensics
Table 85: Roche Enters Into Distribution Agreement With PerkinElmer
Table 86: Pronexus Enters Into Technology Integration Agreement With RealityCorp
Table 87: Carl Zeiss Enters Into Licensing Agreement With Prior Scientific
Table 88: Stratos Product Development Enters Into Co-Development Agreement With Response Biomedical
Table 89: Signal Genetics Enters Into Research And Development Agreement With DiagnoCure
Table 90: Pivotal Therapeutics Enters Into Co-Marketing Agreement With Nutrasource Diagnostics
Table 91: Mitomics Enters Into Licensing Agreement With QDx Pathology Services
Table 92: Biofortuna Enters Into Distribution Agreement With Abbott
Table 93: CML HealthCare Enters Into Licensing Agreement With Phenomenome Discoveries
Table 94: Magellan BioScience Enters Into An Agreement With miacom diagnostics
Table 95: Affymetrix Enters Into Distribution Agreement With Thermo Fisher
Table 96: USD to Local Currency, Canada, Average Actual Rate 2003-2010
List Of Figures
Figure 1: In Vitro Diagnostics, Market Segmentation
Figure 2: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, 2003-2017
Figure 3: In Vitro Diagnostics Market, Canada, Revenue Mix ($m), 2010
Figure 4: In Vitro Diagnostics Market, Canada, Category Contribution (%), 2010
Figure 5: In Vitro Diagnostics, Canada, Cross-Category Analysis, 2003-2017
Figure 6: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, Historic, 2003-2010
Figure 7: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
Figure 8: In Vitro Diagnostics, Canada, Company share (%), 2010
Figure 9: Clinical Chemistry, Market Segmentation
Figure 10: Clinical Chemistry Market, Canada, Revenue Mix ($m), 2010
Figure 11: Clinical Chemistry Market, Canada, Segment Contribution (%), 2010
Figure 12: Clinical Chemistry, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 13: Clinical Chemistry, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 14: Clinical Chemisty Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 15: Clinical Chemisty Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 16: Urine Analysis, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 17: Urine Analysis, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 18: Clinical Chemistry, Canada, Company share (%), 2010
Figure 19: Genetic Testing, Market Segmentation
Figure 20: Genetic Testing Market, Canada, Revenue Mix ($m), 2010
Figure 21: Genetic Testing Market, Canada, Segment Contribution (%), 2010
Figure 22: Genetic Testing, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 23: Genetic Testing, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 24: Genetic Testing, Canada, Company share (%), 2010
Figure 25: Haematology, Market Segmentation
Figure 26: Haematology Market, Canada, Revenue Mix ($m), 2010
Figure 27: Haematology Market, Canada, Segment Contribution (%), 2010
Figure 28: Haematology, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 29: Haematology, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 30: Haematology Reagents, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 31: Haematology Reagents, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 32: Immunohaematology, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 33: Immunohaematology, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 34: Haemostasis, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 35: Haemostasis, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 36: Haematology Rapid Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 37: Haematology Rapid Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 38: Haematology Cell Counters, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 39: Haematology Cell Counters, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 40: Haematology, Canada, Company share (%), 2010
Figure 41: Histology And Cytology, Market Segmentation
Figure 42: Histology And Cytology Market, Canada, Revenue Mix ($m), 2010
Figure 43: Histology And Cytology Market, Canada, Segment Contribution (%), 2010
Figure 44: Histology And Cytology, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 45: Histology And Cytology, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 46: Histology And Cytology, Canada, Company share (%), 2010
Figure 47: Immuno Chemistry Market, Canada, Revenue Mix ($m), 2010
Figure 48: Immuno Chemistry Market, Canada, Segment Contribution (%), 2010
Figure 49: Immuno Chemistry, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 50: Immuno Chemistry, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 51: Disease Specific Immunochemistry, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 52: Disease Specific Immunochemistry, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 53: Drugs of Abuse / Toxicology, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 54: Drugs of Abuse / Toxicology, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 55: Endocrinology Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 56: Endocrinology Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 57: Therapeutic Drug Monitoring, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 58: Therapeutic Drug Monitoring, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 59: Immunochemistry Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 60: Immunochemistry Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 61: Immuno Chemistry, Canada, Company share (%), 2010
Figure 62: Infectious Immunology, Market Segmentation
Figure 63: Infectious Immunology Market, Canada, Revenue Mix ($m), 2010
Figure 64: Infectious Immunology Market, Canada, Segment Contribution (%), 2010
Figure 65: Infectious Immunology, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 66: Infectious Immunology, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 67: Infectious Immunology, Canada, Company share (%), 2010
Figure 68: Microbiology Culture, Market Segmentation
Figure 69: Microbiology Culture Market, Canada, Revenue Mix ($m), 2010
Figure 70: Microbiology Culture Market, Canada, Segment Contribution (%), 2010
Figure 71: Microbiology Culture, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 72: Microbiology Culture, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 73: Microbiology Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 74: Microbiology Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 75: Microbiology Culture, Canada, Company share (%), 2010
Figure 76: Siemens Healthcare, Company Share (%),Canada In Vitro Diagnostics Market, 2010
Figure 77: Abbott Laboratories, Company Share (%),Canada In Vitro Diagnostics Market, 2010
Figure 78: F. Hoffmann-La Roche Ltd., Company Share (%),Canada In Vitro Diagnostics Market, 2010
Figure 79: Beckman Coulter, Inc., Company Share (%),Canada In Vitro Diagnostics Market, 2010
Figure 80: Ortho-Clinical Diagnostics Inc., Company Share (%),Canada In Vitro Diagnostics Market, 2010
Figure 81: bioMerieux S.A., Company Share (%),Canada In Vitro Diagnostics Market, 2010
